Home   Health Tips   Health Concerns    Site Index    Search    Glossary    Contact Us

Visit our Health Index for More Subjects, Conditions and Answers

U.K. study casts doubt on antidepressant drugs

2009

Researchers led by Irving Kirsch of the University of Hull reviewed a series of studies, both published and unpublished, on four antidepressants, examining the question of whether a person's response to these drugs hinged on how depressed they were before getting treatment.

They were Eli Lilly and Co.'s Prozac, also known as fluoxetine, Wyeth's Effexor, also called venlafaxine; GlaxoSmithKline's Paxil, also called Seroxat or paroxetine, and Bristol-Myers Squibb Co's drug Serzone, also called nefazodone, which it no longer markets in the United States.

,,, The researchers obtained data on all the clinical trials submitted to the U.S. Food and Drug Administration for the licensing of the four drugs.

"Although patients get better when they take antidepressants, they also get better when they take a placebo, and the difference in improvement is not very great. This means that depressed people can improve without chemical treatments," Kirsch said in a statement.

JAMA also talks about the study



Prozac, used by 40m people, does not work say scientists

A single Prozac capsule.

Prozac, the bestselling antidepressant taken by 40 million people worldwide, does not work and nor do similar drugs in the same class, according to a major review released today.

The study examined all available data on the drugs, including results from clinical trials that the manufacturers chose not to publish at the time. The trials compared the effect on patients taking the drugs with those given a placebo or sugar pill.

 ... "Given these results, there seems little reason to prescribe antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed," says Kirsch. "This study raises serious issues that need to be addressed surrounding drug licensing and how drug trial data is reported."

The paper, published today in the journal PLoS (Public Library of Science) Medicine, is likely to have a significant impact on the prescribing of the drugs. The National Institute for Health and Clinical Excellence (Nice) already recommends that counselling should be tried before doctors prescribe antidepressants. Kirsch, who was one of the consultants for the guidelines, says the new analysis "would suggest that the prescription of antidepressant medications might be restricted even more".

The review breaks new ground because Kirsch and his colleagues have obtained for the first time what they believe is a full set of trial data for four antidepressants.

They requested the full data under freedom of information rules from the Food and Drug Administration, which licenses medicines in the US and requires all data when it makes a decision.


More here: http://www.guardian.co.uk/society/2008/feb/26/mentalhealth.medicalresearch 


 


If you would like to receive the McVitamins.com Weekly Newsletter,  Please Sign up by clicking here:  Newsletter Signup

We take privacy and security seriously, read about it here


 

Search this Website 

Home    Health Tips   Health Concerns   Site Index   Glossary

© 2000-2017  McVitamins.com
.  All Rights Reserved. Reproduction of this website in full or in part is prohibited without the express written permission of McVitamins.com

We have used our best judgment in compiling this information. The Food and Drug Administration may not have evaluated the information presented. Any reference to a specific product is for your information only and is not intended to diagnose, treat, cure, or prevent any disease